Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 10/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9509221 | 0.85 | CRHBP (0.54) | CRHBPCRHR2MAPTMAPK1TDP1 | |
| SCHEMBL7997158 | 0.85 | CRHBP (0.54) | CRHBPCRHR2MAPTMAPK1TDP1 | |
| SCHEMBL8742125 | 0.83 | CRHBP (0.58) | CRHBPCRHR2MAPTMAPK1TDP1 | |
| SCHEMBL1596478 | 0.83 | CRHBP (0.58) | CRHBPCRHR2MAPTMAPK1TDP1 | |
| SCHEMBL5945876 | 0.83 | CRHBP (0.58) | CRHBPCRHR2MAPTMAPK1TDP1 | |
| SCHEMBL9375780 | 0.83 | ALDH1A1 (0.54) | MAPTMAPK1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL9375784 | 0.83 | ALDH1A1 (0.54) | MAPTMAPK1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6370508 | 0.79 | MAPT (0.42) | CRHBPCRHR2MAPTMAPK1TDP1 | |
| SCHEMBL8742128 | 0.79 | CRHBP (0.56) | CRHBPCRHR2MAPTMAPK1TDP1 | |
| SCHEMBL4301791 | 0.79 | CRHBP (0.56) | CRHBPCRHR2MAPTMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | CRHBP 3145/4885CRHR2 281/4885MAPT 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.